INTRODUCTION: Convulsions are usually events for those who are present and are an
important cause of pediatric emergency visits. Phenobarbital consists of a barbiturate drug
that acts on the central nervous system, used to prevent the onset of seizures in individuals
with epilepsy or seizures of other origins. Several works demonstrate high efficiency of HDLs
in controlled drug release systems making them one of the inorganic materials pointed out as
promising to be used as a support for the storage and sustained release of the intercalated
substance. OBJECTIVES: This study aims to evaluate the efficacy of slow release
phenobarbital in the control of convulsions triggered by pentilenotetrazol, verifying the time
of permanence in the anticonvulsant effect through behavior and electroencephalographic
records. METHODS: A quantitative experimental study was carried out at the Laboratory of
Pharmacology and Toxicology of Natural Products of the Biological Sciences Institute of the
Federal University of Pará. A total of 162 adult male Wistar rats weighing between 200 and
250g were divided into two groups, one for behavioral analysis (n = 90) and biochemistry and
another for the acquisition of electrocorticographic record (n = 72). Hepatic enzymes were
measured by obtaining a blood sample from the animals studied and analyzed in the
Laboratory of Clinical Analysis of the Biological Sciences Institute of the Federal University
of Pará by means of a biochemical analysis of liver function of the Wiener lab GROUP,
model CM 200. The procedure for electrode implant and electrocorticographic recordings
were performed as described by Hamoy (2018, p. 55-56). The values of the results were
described as mean and standard deviation. Power comparisons will be made using ANOVA
and Turkey test using GraphPadPrism ® 5 software. RESULTS: With the withdrawal of
phenobarbital for a period of 36 hours, the animals evolved from the convulsive stage to stage
V after induction with pentylenotetrazole, but the animals that received intercalated
phenobarbital presented higher latencies for the triggering of the convulsive condition, which
indicated the permanence of the anticonvulsive effect of the drug. The use of non-intercalated
and intercalated phenobarbital did not increase the ALT enzyme in relation to the control
group, maintaining the enzyme close to the normality standards, unlike what was observed
when analyzing the AST enzyme, in which the use of non-intercalated phenobarbital induced
a significant increase in AST compared to the control group, which may suggest a certain
hepatic impairment. CONCLUSION: Both drugs, intercalated phenobarbital and non intercalated phenobarbital, exert safety against PTZ-induced seizures in 12, 24 and 36 hours.
However, after 36 hours of PBTI use, a higher protective effect was observed because this
compound had a longer residence time in the organism.
|
